1168 related articles for article (PubMed ID: 27387559)
1. GSK-3 directly regulates phospho-4EBP1 in renal cell carcinoma cell-line: an intrinsic subcellular mechanism for resistance to mTORC1 inhibition.
Ito H; Ichiyanagi O; Naito S; Bilim VN; Tomita Y; Kato T; Nagaoka A; Tsuchiya N
BMC Cancer; 2016 Jul; 16():393. PubMed ID: 27387559
[TBL] [Abstract][Full Text] [Related]
2. Acquired resistance to temsirolimus in human renal cell carcinoma cells is mediated by the constitutive activation of signal transduction pathways through mTORC2.
Harada K; Miyake H; Kumano M; Fujisawa M
Br J Cancer; 2013 Oct; 109(9):2389-95. PubMed ID: 24091619
[TBL] [Abstract][Full Text] [Related]
3. TNF-α induces epithelial-mesenchymal transition of renal cell carcinoma cells via a GSK3β-dependent mechanism.
Ho MY; Tang SJ; Chuang MJ; Cha TL; Li JY; Sun GH; Sun KH
Mol Cancer Res; 2012 Aug; 10(8):1109-19. PubMed ID: 22707636
[TBL] [Abstract][Full Text] [Related]
4. 4EBP1/eIF4E and p70S6K/RPS6 axes play critical and distinct roles in hepatocarcinogenesis driven by AKT and N-Ras proto-oncogenes in mice.
Wang C; Cigliano A; Jiang L; Li X; Fan B; Pilo MG; Liu Y; Gui B; Sini M; Smith JW; Dombrowski F; Calvisi DF; Evert M; Chen X
Hepatology; 2015 Jan; 61(1):200-13. PubMed ID: 25145583
[TBL] [Abstract][Full Text] [Related]
5. Rapamycin attenuates BAFF-extended proliferation and survival via disruption of mTORC1/2 signaling in normal and neoplastic B-lymphoid cells.
Zeng Q; Qin S; Zhang H; Liu B; Qin J; Wang X; Zhang R; Liu C; Dong X; Zhang S; Huang S; Chen L
J Cell Physiol; 2018 Jan; 233(1):516-529. PubMed ID: 28300280
[TBL] [Abstract][Full Text] [Related]
6. Benchmarking effects of mTOR, PI3K, and dual PI3K/mTOR inhibitors in hepatocellular and renal cell carcinoma models developing resistance to sunitinib and sorafenib.
Serova M; de Gramont A; Tijeras-Raballand A; Dos Santos C; Riveiro ME; Slimane K; Faivre S; Raymond E
Cancer Chemother Pharmacol; 2013 May; 71(5):1297-307. PubMed ID: 23479136
[TBL] [Abstract][Full Text] [Related]
7. Ubiquilin-mediated Small Molecule Inhibition of Mammalian Target of Rapamycin Complex 1 (mTORC1) Signaling.
Coffey RT; Shi Y; Long MJ; Marr MT; Hedstrom L
J Biol Chem; 2016 Mar; 291(10):5221-33. PubMed ID: 26740621
[TBL] [Abstract][Full Text] [Related]
8. A comparison of Ku0063794, a dual mTORC1 and mTORC2 inhibitor, and temsirolimus in preclinical renal cell carcinoma models.
Zhang H; Berel D; Wang Y; Li P; Bhowmick NA; Figlin RA; Kim HL
PLoS One; 2013; 8(1):e54918. PubMed ID: 23349989
[TBL] [Abstract][Full Text] [Related]
9. The synergistic inhibition of breast cancer proliferation by combined treatment with 4EGI-1 and MK2206.
Wang H; Huang F; Wang J; Wang P; Lv W; Hong L; Li S; Zhou J
Cell Cycle; 2015; 14(2):232-42. PubMed ID: 25607647
[TBL] [Abstract][Full Text] [Related]
10. Endothelial replicative senescence delayed by the inhibition of MTORC1 signaling involves MicroRNA-107.
Khor ES; Wong PF
Int J Biochem Cell Biol; 2018 Aug; 101():64-73. PubMed ID: 29857052
[TBL] [Abstract][Full Text] [Related]
11. The tumor suppressor NDRG2 cooperates with an mTORC1 inhibitor to suppress the Warburg effect in renal cell carcinoma.
Li X; Hou G; Zhu Z; Yan F; Wang F; Wei D; Zheng Y; Yuan J; Zheng W; Zhang G; Meng P; Guo Y; Li X; Yao L; Shen L; Yuan J
Invest New Drugs; 2020 Aug; 38(4):956-966. PubMed ID: 31463638
[TBL] [Abstract][Full Text] [Related]
12. Upregulation of mTORC2 activation by the selective agonist of EPAC, 8-CPT-2Me-cAMP, in prostate cancer cells: assembly of a multiprotein signaling complex.
Misra UK; Pizzo SV
J Cell Biochem; 2012 May; 113(5):1488-500. PubMed ID: 22173835
[TBL] [Abstract][Full Text] [Related]
13. Constitutive activation of phosphatidyl-inositide 3 kinase contributes to the survival of Hodgkin's lymphoma cells through a mechanism involving Akt kinase and mTOR.
Dutton A; Reynolds GM; Dawson CW; Young LS; Murray PG
J Pathol; 2005 Mar; 205(4):498-506. PubMed ID: 15714459
[TBL] [Abstract][Full Text] [Related]
14. Blockade of fatty acid synthase induces ubiquitination and degradation of phosphoinositide-3-kinase signaling proteins in ovarian cancer.
Tomek K; Wagner R; Varga F; Singer CF; Karlic H; Grunt TW
Mol Cancer Res; 2011 Dec; 9(12):1767-79. PubMed ID: 21970855
[TBL] [Abstract][Full Text] [Related]
15. AKT inhibition overcomes rapamycin resistance by enhancing the repressive function of PRAS40 on mTORC1/4E-BP1 axis.
Mi W; Ye Q; Liu S; She QB
Oncotarget; 2015 Jun; 6(16):13962-77. PubMed ID: 25961827
[TBL] [Abstract][Full Text] [Related]
16. Involvement of mTORC1 and mTORC2 in regulation of glioblastoma multiforme growth and motility.
Gulati N; Karsy M; Albert L; Murali R; Jhanwar-Uniyal M
Int J Oncol; 2009 Oct; 35(4):731-40. PubMed ID: 19724909
[TBL] [Abstract][Full Text] [Related]
17. Phosphorylation of mTOR and S6RP predicts the efficacy of everolimus in patients with metastatic renal cell carcinoma.
Li S; Kong Y; Si L; Chi Z; Cui C; Sheng X; Guo J
BMC Cancer; 2014 May; 14():376. PubMed ID: 24886512
[TBL] [Abstract][Full Text] [Related]
18. Inhibition of GSK-3β activity can result in drug and hormonal resistance and alter sensitivity to targeted therapy in MCF-7 breast cancer cells.
Sokolosky M; Chappell WH; Stadelman K; Abrams SL; Davis NM; Steelman LS; McCubrey JA
Cell Cycle; 2014; 13(5):820-33. PubMed ID: 24407515
[TBL] [Abstract][Full Text] [Related]
19. Longitudinal inhibition of PI3K/Akt/mTOR signaling by LY294002 and rapamycin induces growth arrest of adult T-cell leukemia cells.
Ikezoe T; Nishioka C; Bandobashi K; Yang Y; Kuwayama Y; Adachi Y; Takeuchi T; Koeffler HP; Taguchi H
Leuk Res; 2007 May; 31(5):673-82. PubMed ID: 17007924
[TBL] [Abstract][Full Text] [Related]
20. Both mTORC1 and mTORC2 are involved in the regulation of cell adhesion.
Chen L; Xu B; Liu L; Liu C; Luo Y; Chen X; Barzegar M; Chung J; Huang S
Oncotarget; 2015 Mar; 6(9):7136-50. PubMed ID: 25762619
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
